> Details

Al-Batran, Salah-Eddin; Lorenzen, Sylvie; Thuss-Patience, Peter C.; Homann, Nils; Schenk, Michael; Lindig, Udo; Heuer, Vera; Kretzschmar, Albrecht; Goekkurt, Eray; Haag, Georg Martin; Riera Knorrenschild, Jorge; Bolling, Claus; Hofheinz, Ralf-Dieter; Angermeier, Stefan; Ettrich, Thomas Jens; Siebenhuener, Alexander; Kopp, Christina; Pauligk, Claudia; Goetze, Thorsten Oliver; Gaiser, Timo

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK
  • Contributor: Al-Batran, Salah-Eddin; Lorenzen, Sylvie; Thuss-Patience, Peter C.; Homann, Nils; Schenk, Michael; Lindig, Udo; Heuer, Vera; Kretzschmar, Albrecht; Goekkurt, Eray; Haag, Georg Martin; Riera Knorrenschild, Jorge; Bolling, Claus; Hofheinz, Ralf-Dieter; Angermeier, Stefan; Ettrich, Thomas Jens; Siebenhuener, Alexander; Kopp, Christina; Pauligk, Claudia; Goetze, Thorsten Oliver; Gaiser, Timo
  • Published: American Society of Clinical Oncology (ASCO), 2022
  • Published in: Journal of Clinical Oncology, 40 (2022) 16_suppl, Seite 4003-4003
  • Language: English
  • DOI: 10.1200/jco.2022.40.16_suppl.4003
  • ISSN: 0732-183X; 1527-7755
  • Origination:
  • Footnote:
  • Description: 4003 Background: DANTE evaluates atezolizumab in the perioperative treatment of resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with FLOT. Here, we report interim results. Methods: DANTE is a multicenter, investigator-initiated, phase IIb trial. Patients (pts) with resectable adenocarcinoma of the stomach and GEJ (≥cT2 and/or N+) were randomized to receive 4+4 cycles of periop. FLOT chemotherapy (arm B) or the same regime with additional atezolizumab at 840 mg, q2w, followed by atezolizumab monotherapy for 8 cycles at 1200 mg, q3w (arm A). The primary endpoint is progression-free survival. The secondary endpoints surgical outcome (pTNM, R0 resection rate and periop. morbidity/mortality), path. regression and safety are reported here. TNM stage was evaluated by local pathologists and path. regression (Becker-Classification) by local and central pathologists. PD-L1 and MSI status were centrally evaluated. Results: In total, 295 pts were randomized (A, 146; B, 149) with baseline characteristics as follows: median age 61y, male 74%, intestinal type 42%, GEJ 61%, cT3/4 77%, N+ 78%. Twenty-five pts (8.5%) were MSI; 50% had PD-L1 CPS ≥1, 23% PD-L1 CPS ≥5 and 15% PD-L1 CPS ≥10. Pre-op FLOT cycles were completed in 93% of pts and post-op cycles in 43% of pts, with no difference between arms. Surgical morbidity (A, 45%; B, 43%) and mortality (overall 2.5%) were comparable between arms, as were R0-resection rates (arm A, 92% vs. arm B, 91%). Downsizing favored arm A vs B (pT0, 23% vs 15%; pN0, 68% vs 54%). Increases in path. regression rates were seen, particularly with higher PD-L1 expression (Table). Conclusions: The analysis shows beneficial effects of atezolizumab combined with FLOT vs FLOT alone on path. stage and path. regression that seem to be more pronounced with higher PD-L1 expression. Sponsor: Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest. EudraCT: 2017-001979-23. Clinical trial information: NCT03421288. [Table: see text]
  • Access State: Open Access